Literature DB >> 25216841

Monitoring liver function among patients who initiated anti-tuberculosis drugs in Taiwan, 2000-2011.

H-C Chou1, S-W Lin2, W-W Chen1, W-M Ke1, P-H Chao1, F-Y Hsiao2.   

Abstract

OBJECTIVE: To investigate adherence to liver function monitoring as recommended in Taiwan's tuberculosis (TB) diagnosis and treatment guidelines for newly diagnosed TB patients.
DESIGN: Retrospective cohort study of the National Health Insurance Research Database (NHIRD), Taiwan, 2000-2011.
METHODS: From the NHIRD, we identified 11 397 newly diagnosed TB patients who initiated anti-tuberculosis treatment between 2000 and 2011 and categorised these into three groups: completely, partially and non-adherent. Logistic regression was used to explore potential factors associated with the adherence rate.
RESULTS: The completely adherent rate increased from 0.5% in 2000 to 9.2% in 2011, while the non-adherent rate decreased from 17.5% to 1.2%. Compared to the non-adherent group, patients with a history of liver disease (OR 4.36, 95%CI 1.92-9.87) and viral hepatitis (OR 9.39, 95%CI 1.47-60.19), as well as patients whose prescribing physicians were specialists in chest (OR 4.59, 95%CI 1.91-11.05), TB (OR 2.55, 95%CI 1.01-6.40) and infectious diseases (OR 3.93, 95%CI 1.08-14.31), had higher odds of being completely adherent to the guidelines.
CONCLUSION: Our findings could serve as an important reference for developing effective strategies to improve adherence to guidelines and prevent patients from developing anti-tuberculosis drug-associated hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25216841     DOI: 10.5588/ijtld.14.0155

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Liver Test Monitoring: Real-World Compliance for Drugs with Monitoring Requirements at 2-Week Intervals or More Frequently.

Authors:  Marsha A Wilcox; Jill Hardin; James Weaver; Erica A Voss
Journal:  Pharmaceut Med       Date:  2019-10

2.  Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Authors:  Conor Duncan Tweed; Genevieve Helen Wills; Angela M Crook; Rodney Dawson; Andreas H Diacon; Cheryl E Louw; Timothy D McHugh; Carl Mendel; Sarah Meredith; Lerato Mohapi; Michael E Murphy; Stephen Murray; Sara Murthy; Andrew J Nunn; Patrick P J Phillips; Kasha Singh; M Spigelman; S H Gillespie
Journal:  BMC Med       Date:  2018-03-28       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.